<DOC>
	<DOCNO>NCT02005562</DOCNO>
	<brief_summary>This study compare incidence acute clinical subclinical rejection immunosuppression CellCept start dose 3mg po daily therapeutic drug monitor standard immunosuppression CellCept fix dose 2g po daily , kidney transplant recipient receive induction anti-IRL2 , cyclosporine therapy , early discontinuation steroid . Patients randomize one two treatment arm . The anticipated time study treatment 52 week .</brief_summary>
	<brief_title>OPERA Study : A Study Two Dosing Regimens CellCept ( Mycophenolate Mofetil ) Kidney Transplant Patients .</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>adult patient , age 1875 year age ; receipt first donor kidney ; eligible receive immunosuppressive treatment comprise IRL2 , CellCept , cyclosporine steroid ; eligible receive oral treatment first day posttransplantation . patient receive second subsequent kidney transplant , multiorgan transplant ; history malignancy last 5 year ( except successfully treat squamous cell basal cell cancer cervical cancer situ ) ; patient active hepatitis B and/or hepatitis C , HIV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>